TY - JOUR
T1 - Elevated plasma levels of calcitonin gene-related peptide in individuals with rosacea
T2 - A cross-sectional case-control study
AU - Wienholtz, Nita K F
AU - Christensen, Casper E
AU - Ashina, Håkan
AU - Jørgensen, Niklas R
AU - Egeberg, Alexander
AU - Thyssen, Jacob P
AU - Ashina, Messoud
N1 - © 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2025/1
Y1 - 2025/1
N2 - BACKGROUND: Understanding the role of calcitonin gene-related peptide (CGRP) in the pathogenesis of rosacea might provide new therapeutic avenues for individuals with this disease.OBJECTIVE: To compare plasma levels of CGRP between individuals with rosacea and healthy controls.METHODS: In this cross-sectional case-control study conducted in Copenhagen, Denmark, we collected blood samples from the antecubital vein from adults with rosacea and from healthy controls.RESULTS: We enrolled 123 individuals with rosacea and 68 healthy controls. After adjusting for age and sex, plasma levels of CGRP were significantly higher in individuals with rosacea (mean, 95% confidence interval: 140.21 pmol/L, 128.50-151.92 pmol/L), compared with controls (110.77 pmol/L, 99.91-120.14 pmol/L, p = 0.002). Plasma levels of CGRP were not affected by age, sex, BMI, concomitant migraine, rosacea sub- or phenotype, concomitant disease or current treatment.LIMITATIONS: Participants were not age-, sex- and BMI-matched.CONCLUSIONS AND RELEVANCE: Elevated plasma levels of CGRP in individuals with rosacea suggest a role of CGRP in the pathogenesis of rosacea. Targeting CGRP signalling might hold therapeutic promise in people affected by this disease.GOV LISTING: NCT03872050.
AB - BACKGROUND: Understanding the role of calcitonin gene-related peptide (CGRP) in the pathogenesis of rosacea might provide new therapeutic avenues for individuals with this disease.OBJECTIVE: To compare plasma levels of CGRP between individuals with rosacea and healthy controls.METHODS: In this cross-sectional case-control study conducted in Copenhagen, Denmark, we collected blood samples from the antecubital vein from adults with rosacea and from healthy controls.RESULTS: We enrolled 123 individuals with rosacea and 68 healthy controls. After adjusting for age and sex, plasma levels of CGRP were significantly higher in individuals with rosacea (mean, 95% confidence interval: 140.21 pmol/L, 128.50-151.92 pmol/L), compared with controls (110.77 pmol/L, 99.91-120.14 pmol/L, p = 0.002). Plasma levels of CGRP were not affected by age, sex, BMI, concomitant migraine, rosacea sub- or phenotype, concomitant disease or current treatment.LIMITATIONS: Participants were not age-, sex- and BMI-matched.CONCLUSIONS AND RELEVANCE: Elevated plasma levels of CGRP in individuals with rosacea suggest a role of CGRP in the pathogenesis of rosacea. Targeting CGRP signalling might hold therapeutic promise in people affected by this disease.GOV LISTING: NCT03872050.
KW - Adult
KW - Aged
KW - Calcitonin Gene-Related Peptide/blood
KW - Case-Control Studies
KW - Cross-Sectional Studies
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Rosacea/blood
UR - http://www.scopus.com/inward/record.url?scp=85189648393&partnerID=8YFLogxK
U2 - 10.1111/jdv.19954
DO - 10.1111/jdv.19954
M3 - Journal article
C2 - 38558478
SN - 0926-9959
VL - 39
SP - 181
EP - 188
JO - Journal of the European Academy of Dermatology and Venereology : JEADV
JF - Journal of the European Academy of Dermatology and Venereology : JEADV
IS - 1
ER -